**Referenca**

1. World Health Organisation. Adherence to long-term therapies: evidence for action [Internet]. Available from : http://www.who. int/chp/knowledge/publications/adherence\_report/en/
2. Uppsala Monitoring Centre. Better Pharmacovigilance for All. Uppsala Reports [Internet].2017;(76). Available from: https://view.publitas.com/uppsala-monitoring-centre/uppsala-reports-76\_web/page/1
3. Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Prefer Adherence. 2017;11:1103-1117.
4. Einarson TR. Patient preferences in severe COPD and asthma: a comprehensive literature review. Int J Chron Obstruct Pulmon Dis. 2015;10:739-744..
5. Deshpande S, Quek RG, Forbes CA, de Kock S, Kleijnen J, Gandra SR, et al. A systematic review to assess adherence and persistence with statins. Curr Med Res Opin. 2017;33:769-778.
6. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PloS Med. 2016;13:e1002183.
7. Smith D, Lovell J, Weller C, Kennedy B, Winbolt M, Young C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One. 2017;12:e0170651.
8. Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35-44.
9. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concern Framework. PLoS One. 2013;8:e80633.
10. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;(2):CD000011.
11. Fraser S. Concordance, compliance, preference or adherence. Patient Prefer Adherence. 2010;4:95–96.
12. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47.
13. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705.
14. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449– 457.
15. Forbes CA, Deshpande S, Sorio-Vilela F, Kutikova L, Duffy S, Gouni-Berthold I, et al. A systematic literature review comparing methods for the measurement of patient persistence and adherence.Curr Med Res Opin. 2018;34:1613–1625.
16. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med. 2005;353:487–497.
17. Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 2015;2015:217047.
18. De Achaval S, Suarez-Almazor ME. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumatol. 2010;5:313-326.
19. Van den Bemt B, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol. 2012;8:337- 351.
20. Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11-S21.
21. Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH. Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2015;67:1656–1663.
22. Chu LH, Kawatkar AA, Gabriel SE. Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients. Clin Ther. 2015;37(3):660–666.e8.
23. Checchi KD, Huybrechts KF, Avorn J, Kesselheim AS. Electronic medication packaging devices and medication adherence: a systematic review. JAMA. 2014;312:1237-1247.
24. El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82:268-279.
25. Shi L, Liu J, Fonseca V, Walker P, Kalsekar A, Pawaskar M. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes. 2010;13;8:99.
26. Nguyen TM, La Caze A, Cottrell N. What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol. 2014;77:427-445.
27. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241-247.
28. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol. 2016;35:1335–1339.
29. Kumar K, Raza K, Nightingale P, Horne R, Chapman S, Greenfield S, et al. Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study. BMC Musculoskelet Disord. 2015;16:396.
30. Klerk E, van der Heijde D, van der Tempel H, van derLinden S. Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol. 1999;26:2635-2641.
31. Hughes LD, Done J, Young A. A 5 item version of the Compliance Questionnaire for Rheumatology (CQR5) successfully identifies low adherence to DMARDs. BMC Musculoskelet Disord. 2013;14:286.
32. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1998;14:1–24.
33. Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc (2003). 2011;51:90-94.
34. Michetti P, Weinman J, Mrowietz U, Smolen J, Peyrin- Biroulet L, Louis E, et al. Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. Adv Ther. 2017;34:91–108.
35. Vries ST, Keers JC, Visser R, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J, et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014;76:134–138.
36. Foot H, La Caze A, Gujral G, Cottrell N. The necessity– concerns framework predicts adherence to medication in multiple illness conditions: A meta-analysis. Patient Educ Couns. 2016;99:706–717.
37. Anghel LA, Farcaş AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence. 2018;12:1151–1166.
38. Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24(1):67-74
39. https://bmjopen.bmj.com/content/8/1/e016982
40. <https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-11-326>
41. Williams AF, Manias E, Walker R: Adherence to multiple, prescribed medications in diabetic kidney disease: A qualitative study of consumers' and health professionals' perspectives. Int J Nurs Stud. 2008, 45 (12): 1742-1756. 10.1016/j.ijnurstu.2008.07.002.
42. 42.Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, Weissman JS: Primary medication non-adherence: analysis of 195, 930 electronic prescriptions. J Gen Intern Med. 25 (4): 284-290.
43. 43.Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV: New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res. 2009, 44 (5 Pt 1): 1640-1661.
44. Bewley A, Page B: Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol

Venereol. 25 (Suppl 4): 9-14.

 45. <https://www.amerisourcebergen.com/insights/pharmacies/nine-tips-for-medication-adherence>

 46.D.T. Lau and D.P. Nau. “Oral Antihyperglycemic Medication Nonadherence and Subsequent Hospitalization

 among Individuals with Type 2 Diabetes,” Diabetes Care, September, 2004.

 47. S.D. Saini et al. “Effect of Medication Dosing Frequency on Adherence in Chronic Diseases.” American

 Journal of Managed Care, June 2009.

 48. S. Bangalore et al. “Fixed Dose Combinations Improve Medication Compliance: A Meta-Analysis.” American

 Journal of Medicine, August 2007.

 49. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication

 nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry

 2002;63:892-909.

 50. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-8.

 51. Colom F, Vieta E, Martinez-Aran A, Reinares M, Benabarre A, Gasto C. Clinical factors

associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000;61:549-55.

 52. Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics.

Am J Health Syst Pharm 2002; 59:Suppl 8:S10-S15.

 53. Gillis LS, Trollip D, Jakoet A, Holden T. Non-compliance with psychotropic medication.

S Afr Med J 1987;72:602-6.

1. American Pharmacists Association (APhA). Pharmacists and the Health Care Puzzle: Improving Medication Use and Reducing Health Care Costs. Washington, DC, 2008. www.chronicdisease.org/resource/resmgr/cvh/pharm\_&\_hc\_puzzle.pdf (accessed May 4, 2012).
2. Balkrishnan, Rajesh, Rukmini Rajagopalan, Fabian T. Camacho, Sally A. Huston, Frederick T. Murray, and Roger T. Anderson. “Predictors of Medication Adherence and Associated Health Care Costs in an Older Population with Type 2 Diabetes Mellitus: A Longitudinal Cohort Study.” Clinical Therapeutics 25 (2003): 2958-2971.
3. Belluck, Pam. “For Forgetful, Cash Helps the Medicine Go Down.” The New York Times, June 13, 2010, Health section.
4. Benner, Josh. “Underuse of Prescription Medications and What It’ll Take to Fix It.” Rx Ante Presentation.November 29, 2012 http://rxante.com/objects/pdfs/Benner\_NCHC\_Adherence\_Nov\_2012.pdf (accessed on March 15, 2013).
5. Brennan, Troyen A., Timothy J. Dollear, Min Hu, Olga S. Matlin, William H. Shrank, Niteesh K. Choudhry, and William Grambley. “An Integrated Pharmacy-Based Program Improved Medication Prescription Adherence Rates in Diabetes Patients.” Health Affairs 31(2012):120-129.
6. Centers for Disease Control and Prevention. “Chronic Diseases and Health Promotion.” http://www.cdc.gov/chronicdisease/overview/index.htm (accessed May 4, 2012).
7. Centers for Disease Control and Prevention and the National Center for Chronic Disease Prevention and Health Promotion. The Power of Prevention: Reducing the Health and Economic Burden of Chronic Disease. Atlanta, GA, April 2003.
8. Center for Connected Health. “Wireless Medication Adherence Study Conducted at the Partners Center for Connected Health Shows Promising Initial Findings.” June 23, 2010. http://www.connected-health.org/media-center/press-releases/wireless-medication-adherence-study-conducted-at-the-partners-center-for-connected-health-shows-promising-initial-findings.aspx (accessed May 4, 2012).
9. Centers for Medicare & Medicaid Services. Choose Higher Quality for Better Health Care. October 2012. http://www.medicare.gov/Publications/Pubs/pdf/11226.pdf (accessed April 27 2013).
10. Centers for Medicare & Medicaid Services. Medicare Health and Drug Plan Quality and Performance Ratings 2013 Part C and Part D Technical Notes. October 10, 2012.
11. Chandra, Amitabah, Jonathan Gruber, and Robin McKnight. “Patient Cost-Sharing and Hospitalization Offsets in the Elderly.” American Economic Review 100 (2010): 193-213.
12. Chang, Andrew, Joshua N. Liberman, Charmaine Coulen, Jan E. Berger, and Troyen A. Brennan. “Value-Based Insurance Design and Antidiabetic Medication Adherence.” American Journal of Pharmacy Benefits (2010) 2: 39-44.
13. Chernew, Michael E., Iver A. Juster, Mayur R. Shah, Arnold Wegh, Stephen N. Rosenberg Allison B. Rosen, Michael C. Sokol, Kristina Yu-Isenberg, and A. Mark Fendrick. “Evidence that Value-Based Insurance Can Be Effective.” Health Affairs. 29 (2010): 530-6.
14. Chernew, Michael E., Mayur R. Shah, Arnold Wegh, Stephen N. Rosenberg, Iver A. Juster, Allison B. Rosen, Michael C. Sokol, Kristina Yu-Isenberg, and A. Mark Fendrick. “Impact of Decreasing Copayments on Medication Adherence within a Disease Management Environment.” Health Affairs 27 (2008): 103–112.
15. Choudry, Niteesh K., Michael A. Fischer, Jerry Avorn, Joshua N. Liberman, Sebastian Schneeweiss, Juliana Pakes, Troyen A. Brennan, and William H. Shrank. “The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications. Archives of Internal Medicine.” 171 (2011):814-822.
16. Congressional Budget Office (CBO). Offsetting Effects of Prescription Drug Use on Medicare’s Spending for Medical Services. November 2012. http://www.cbo.gov/sites/default/files/cbofiles/attachments/43741-MedicalOffsets-11-29-12.pdf (accessed December 28, 2012).
17. Conn, Vicki S., Adam R. Hafdahl, Pamela S. Cooper, Todd M. Ruppar, David R. Mehr, and Cynthia L. Russell. “Interventions to Improve Medication Adherence Among Older Adults: Meta-Analysis of Adherence Outcomes Among Randomized Controlled Trials.” The Gerontologist 49 (2009): 447-462.
18. Cutler, David M., Genia Long, Ernst R. Berndt, Jimmy Royer, Andree-Anne Fournier, Alicia Sasser, and Pierre Cremieux. “The Value of Antihypertensive Drugs: A Perspective on Medical Innovation.” Health Affairs 26 (2007): 97.
19. Cutrona, Sarah L., Niteesh K. Choudhry, Michael A. Fischer, Amber Servi, Joshua N. Liberman, Troyen A. Brennan, and William H. Shrank. “Modes of Delivery for Interventions to Improve Cardiovascular Medication Adherence.” The American Journal of Managed Care 16 (2010): 929-942.
20. D’Amato, Steve. “Improving Patient Adherence with Oral Chemotherapy.” Oncology Issues July/August (2008): 42-45.
21. Delamater, Alan M. “Improving Patient Adherence.” Clinical Diabetes 24 (2006): 71–77.
22. Department of Health and Human Services, Administration on Aging (HHS, AOA). “Aging Statistics.” http://www.aoa.gov/Aging\_Statistics/ (accessed April 27, 2013).
23. Enhanced Online News (EON). “UnitedHealthcare Launches First Diabetes Plan with Incentives for Preventive Care.” January 15, 2009. http://eon.businesswire.com/news/eon/20090115005315/en (accessed April 27, 2013).
24. Esposito, Dominick, Ann D. Bagchi, James M. Verdier, Deo S. Bencio, and Myoung S. Kim. “Medicaid Beneficiaries With Congestive Heart Failure: Association of Medication Adherence with Healthcare Use and Costs.” American Journal of Managed Care 15 (2009): 437-45.
25. Express Scripts. 2011 Drug Trend Report. St. Louis, MO, April 2012.
26. Gaynor, Martin, Jian Li, and William B. Vogt. “Substitution, Spending Offsets, and Prescription Drug Benefit Design.” Forum for Health Economics & Policy 10 (2007): 1-31.
27. Goldman, Dana P., Geoffrey F. Joyce, and Yuhui Zheng. “Prescription Drug Cost Sharing: Associations with Medication and Medical Utilization and Spending and Health.” Journal of the American Medical Association (2007) 298: 61-69.
28. Goldman, Dana P., Geoffrey F. Joyce, Jose J. Escarce, Jennifer E. Pace, Matthew D. Solomon, Marianne Laouri, Pamela B. Landsman, and Steven Teutsch. “Pharmacy Benefits and the Use of Drugs by the Chronically Ill.” Journal of the American Medical Association 291 (2004): 2344-50.
29. Gwadry-Sridhar, Fernida H., Elizabeth Manias, Ying Zhang, Anuja Roy, Kristina Yu-Isenberg, Dyfrig A. Hughes, and Michael B. Nichol. “A Framework for Planning and Critiquing Medication Compliance and Persistence Using Prospective Study Designs.” Clinical Therapeutics 31 (2009): 421-435.
30. The Henry J. Kaiser Family Foundation (KFF). “Medicare Advantage Fact Sheet.” November 30, 2012. http://kff.org/medicare/fact-sheet/medicare-advantage-fact-sheet/ (accessed April 27, 2013).
31. Ho, P. Michael, David J. Magid, Frederick A. Masoudi, David L. McClure, and John S. Rumsfeld. “Adherence to Cardioprotective Medications and Mortality among Patients with Diabetes and Ischemic Heart Disease.” BMC Cardiovascular Disorders 6 (2006).
32. Hsu, John, Mary Price, Jie Huang, Richard Brand, Vicki Fung, Rita Hui, Bruce Fireman, Joseph P. Newhouse, and Joseph V. Selby. “Unintended Consequences of Caps on Medicare Drug Benefits.” New England Journal of Medicine 354 (2006): 2349-2359.
33. Jha, Ashish K., Ronald E. Aubert, Jianying Yao, Russell Teagarden, and Robert S. Epstein. “Greater Adherence to Diabetes Drugs Is Linked to Less Hospital Use And Could Save Nearly $5 Billion Annually.” Health Affairs 31 (2012):1836-1846.
34. Lee, Jeannie K., Karen A. Grace, and Allen J. Taylor. “Effect of a Pharmacy Care Program on Medication Adherence and Persistence, Blood Pressure, and Low-Density Lipoprotein Cholesterol: A Randomized Controlled Trial.” Journal of the American Medical Association 296 (2006): 2563–2571.
35. Marrufo, Grecia, Anjali Dixit, Daniella Perlroth, Alejandro Montesinos, Emil Rusev, and Michael Packard. Medication Therapy Management in a Chronically Ill Population: Interim Report. Acumen, LLC, January 2013.
36. McWilliams, J. Michael, Alan M. Zaslavsky, and Haiden A. Huskamp. “Implementation of Medicare Part D and Nondrug Medical Spending for Elderly Adults With Limited Prior Drug Coverage.” Journal of the American Medical Association 306 (2011):403-409.
37. Meichenbaum, Donald and Dennis C. Turk. Facilitating Treatment Adherence: A Practitioner’s Guidebook. New York, NY: Plenum Press; 1987.
38. New England Health Institute (NEHI). Thinking Outside the Pillbox: A System-wide Approach to Improving Patient Medication Adherence for Chronic Disease. Cambridge, MA, 2009.
39. Osterberg, Lars and Terrence Blaschke. “Drug Therapy: Adherence to Medication.” New England Journal of Medicine 353 (2005): 487-97.
40. Parks Thomas, Cindy.How Prescription Drug Use Affects Healthcare Utilization and Spending by Older Americans: A Review of the Literature. AARP Public Policy Institute. April 2008 http://assets.aarp.org/rgcenter/health/2008\_04\_rx.pdf (accessed May 4, 2012).
41. Pharmaceutical Research and Manufacturers of America (PhRMA). “Adherence: Key Information on Managing and Treating Disease.” http://phr-dev.wcgwork.com/issues/adherence (accessed May 15, 2013).
42. Pharmaceutical Research and Manufacturers of America (PhRMA). “Medicare Part D: A Success Story,” http://www.phrma.org/issues/medicare (accessed May 16, 2013).
43. Pittman, Donald G., William Chen, Steven J. Bowlin, and JoAnne M. Foody. “Adherence to Statins, Subsequent Healthcare Costs, and Cardiovascular Hospitalizations.” American Journal of Cardiology 107 (2011): 1662-1666.
44. Qato, Dima M., G. Caleb Alexander, Rena M. Conti, Michael Johnson, Phil Schumm, Stacy Tessler Lindau. “Use of Prescription and Over the Counter Medications and Dietary Supplements Among Older Adults in the United States.” Journal of the American Medical Association 300 (2008): 2867-2878.
45. Roebuck, M. Christopher, Joshua N. Liberman, Marin Gemmill-Toyama and Troyen A. Brennan. “Medication Adherence Leads to Lower Health Care Use and Costs Despite Increased Drug Spending.” Health Affairs 30 (2011): 91-99.
46. Sabate, Eduardo.,ed., Adherence to Long-Term Therapies: Evidence for Action. World Health Organization. Geneva, Switzerland. 2003.
47. Sansone, Randy A. and Lori A. Sansone. “Antidepressant Adherence: Are Patients Taking their Medications?” Innovations in Clinical Neuroscience 9(2012): 41-46.
48. Sokol, Michael C., Kimberly A. McGuigan, Robert R. Verbrugge, and Robert S. Epstein. “Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost.” Medical Care 43 (2005): 521-530.
49. Streeter, Sonya Blesser, Lee Schwartzberg, Nadia Husain, and Michael Johnsrud. “Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions.” Journal of Oncology Practice 7 (2011):48s-51s.
50. Stuart, Bruce C., Amy Davidoff, Ruth Lopert, Thomas Shaffer, J. Samantha Shoemaker, and Jennifer Lloyd. “Does Medication Adherence Lower Medicare Spending among Beneficiaries with Diabetes?” Health Services Research 46 (2011): 1180-1199.
51. Stuart, Bruce C., Jalpa A. Doshi, Joseph V. Terza. “Assessing the Impact of Drug Use on Hospital Costs.” Health Services Research (2009) 44: 128-144.
52. Taitel, Michael, Jenny Jiang, Kristi Rudkin, Susan Ewing, and Ian Duncan. “The Impact of Pharmacist Face to Face Counseling to Improve Medication Adherence Among Patients Initiating Statin Therapy.” Patient Preference and Adherence 6 (2012): 323-329.
53. Wilson, Jerome, Kristen Axelsen, and Simon Tang. “Medicaid Prescription Drug Access Restrictions: Exploring the Effect on Patient Persistence with Hypertension Medications.” American Journal of Managed Care (11) 2005: SP27-SP34.
54. UnitedHealthcare. “ ‘Refill and Save Program’ Rewards Prescription Drug Compliance with Discounts on Select Medications.” February 1, 2010 http://www.reuters.com/article/2010/02/01/idUS135238+01-Feb-2010+BW20100201 (accessed May 4, 2012).
55. Wu, Shin-Yi and A. Green. Projection of Chronic Illness Prevalence and Cost Inflation. RAND Corporation, October 2000.
56. Zeng, Feng, Bimal Patel and Louis Brunetti. “Effects of Coverage Gap Reform on Adherence to Diabetes Medications.” American Journal of Managed Care 19 (2013): 308-316.
57. Zyczynski, Teresa M. and Karin S. Coyne. “Hypertension and Current Issues in Compliance and Patient Outcomes.” Current Hypertension Reports 2 (2000): 510-514.
58. Haskard Zolnierek KB, DiMatteo. Physician communication and patient adherence to treatment: a meta-analysis. MedCare. 2009; 47(8): 826-834.
59. Cooper LA, Roter DL, Bone LR, et al. A randomized controlled trial of interventions to enhance patient-physician partnership, patient adherence and high blood pressure control among ethnic minorities and poor persons: study protocol NCT00123045. Implement Sci. 2009; 19; 4:7.
60. Sabate E. Adherence to long-term therapies. Evidence for action. 2003. Geneva, Switzerland: World Health Organization 2003 [http://www.who.int/chp/knowledge/publications/adherence\_report/en/index.html. Accessed 1/12/2011](http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html.%20Accessed%201/12/2011).
61. American Society of Consultant Pharmacists. Adult Meducation. Improving medication adherence in older adults.http://www.adultmeducation.com/downloads/Adult\_Meducation.pdf. Accessed 1/12/2011.
62. Wroth TH, Pathman DE. Primary medication adherence in a rural population: the role of the patient-physician relationship and satisfaction with care. J Am Board Fam Med. 2006; 19(5): 478-486.
63. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. MedCare. 2002; 40:794-811. (in Kripalani)
64. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005; 43:521-530.
65. Piette JD, Heisler M, Krein S. The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med. 2005; 165; 1749-1755
66. Kravitz RL, Melnikow J. Medical adherence research: time for a change in direction. Med Care. 2004; 42; 197-199.
67. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence terminology and definitions. Value Health.2008; 11: 44-47.
68. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med. 1990l; 150(7): 1377-1378
69. Haynes RB, Montague P, Oliver T, et al. Interventions for helping patients to follow prescriptions for medications.
70. Cochrane Database Syst Rev. 2000;(2): CD000011. 5.a. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications.
71. Atreja A, Bellam N, Levy S. Strategies to enhance patient adherence: Making it simple. Medacapt Gen Med. 2005:7(1): 4.
72. Kripalani S, Yao X, Haynes B. Interventions to enhance medication adherence in chronic medical conditions. Arch InternMed. 2007; 167(6): 540-549.
73. Domino FJ. Cochrane for Clinicians. Improving adherence to treatment for hypertension. Am Fam. Physician. 2005;71(11) 2089-2090.
74. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence. 2010; 4:51-60.
75. . McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions.JAMA.2002; 288; 22:2868-2879.
76. National Association of Chain Drug Stores, Pharmacies: Improving Health, Reducing Costs, July 2010. Based on IMSHealth data.
77. DiMatteo MR. Variation in patients’ adherence to medical recommendations. Medical Care. 2004; 42(3); 200-209.
78. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28: 1411–1424.
79. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47.
80. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
81. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289: 1107–1116.
82. Heidenreich PA. Patient adherence: the next frontier in quality improvement. Am J Med. 2004;1 17:130–132.
83. Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother. 2004;38:1363–1368.
84. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24: 67–74.
85. Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med. 2007;167:1798–1803.
86. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772–779.
87. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40: 1280–1288.
88. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–116.
89. Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, Daley WL, Gurwitz J, Hollenberg NK. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension. 2006;47:1039–1048.
90. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–574.
91. Bryson CL, Au DH, Young B, McDonell MB, Fihn SD. A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care. 2007;45:497–504.
92. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;1 17:1028–1036.
93. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166:1842–1847.
94. Newby LK, LaPointe NMA, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203–212.
95. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462–467.
96. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–1117.
97. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive mono- therapy in 13 managed care organizations. J Manag Care Pharm. 2006; 12:239–245.
98. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P, Sřrensen R, Folke F, Gadsbřll N, Rasmussen S, Křber
99. L, Madsen M, Torp-Pedersen C. Persistent use of evidence-based pharmacotherapy in heart failure is associated
100. Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet. 1997;32:345–356.
101. Makaryus AN, Friedman EA. Patients’ understanding of their treatment plans and diagnosis at discharge. Mayo Clin Proc. 2005;80:991–994.